Two kinds of clot, two different questions
Clots in arteries usually form on fatty plaque and cause heart attacks and strokes; NHLBI notes that plaque makes clots in arteries more likely. [9] Clots in veins form where blood slows down or a vein is damaged, most often in the leg, thigh or pelvis (DVT), and can travel to the lungs (PE). [9] Together, DVT and PE are called venous thromboembolism, or VTE.
SELECT, the trial behind Wegovy®’s heart indication, measured the arterial side. It enrolled 17,604 adults aged 45 or older with established cardiovascular disease, a BMI of 27 or more and no diabetes. The primary outcome, cardiovascular death, non-fatal heart attack or non-fatal stroke, occurred in 6.5% on semaglutide and 8.0% on placebo. [4] The label lists this as an approved use. [1] That result does not tell us about leg or lung clots.
| Source | Arterial events (heart attack, stroke) | Vein clots (DVT, PE) |
|---|---|---|
| US label [1] | Approved to reduce major cardiovascular events (section 1) | Not listed in sections 6.1 or 6.2 |
| SELECT trial [4] | Primary outcome 6.5% vs 8.0% on placebo | Not reported in the abstract |
| EU summary of product characteristics [2] | — | Not listed in Table 3 |
| Canadian monograph [3] | — | Not listed in sections 8.2, 8.3 or 8.5 |
What studies of vein clots show
Two 2025 meta-analyses of randomised trials of GLP-1 medicines reached different answers. The first pooled 39 trials with 70,499 participants, against placebo or other diabetes drugs. Overall VTE showed a non-significant upward trend, while DVT alone was more frequent (odds ratio 1.64), with the excess concentrated in trials lasting more than 18 months (odds ratio 2.32) and in cardiovascular outcome trials (2.18). PE did not differ. [5] SELECT is that kind of long heart trial, but the abstract does not say how much it contributed.
The second included only placebo-controlled trials, 27 of them with 84,003 patients. It found no significant difference in overall VTE and a lower risk of PE (risk ratio 0.60). [6] Neither analysis gives a Wegovy®-specific figure, and clots were rare in both, so small numbers of events can move the results.
Reports and smaller studies
- Adverse event reports: a 2026 analysis of FDA reports from 2020 to 2025 found 1,618 clot reports with GLP-1 medicines but no disproportionate reporting overall, with the lowest ratio for vein clots. Compared with orlistat, another weight-loss medicine, GLP-1 medicines had lower odds of vein-clot reports. [7] Spontaneous reports cannot show cause or frequency.
- Surgery: in a 60-woman observational study of tummy-tuck surgery after weight loss, those who had used semaglutide or tirzepatide beforehand had smaller rises in clotting and inflammation markers and no symptomatic clots, against two in the lifestyle group. [8] The study was small and not randomised.
- Single case reports of clots on semaglutide exist, but individual cases cannot separate the medicine from other risk factors.
How Wegovy® might matter, and how it might not
- Label-supported route to watch: vomiting and diarrhea can lead to dehydration, which the label links to kidney injury. [1] Whether dehydration on Wegovy® raises clot risk has not been studied.
- Proposed: weight loss reduces one established risk factor, obesity, [9][10] and the surgery study above hints at lower clotting markers, but no trial has shown fewer vein clots on Wegovy®.
- Label fact with indirect relevance: Wegovy® does not change blood levels of the hormones in a common contraceptive pill. [1] Estrogen-containing contraception remains a clot risk factor in its own right. [10]
Risk factors that matter whatever you take
NHLBI and CDC describe vein clots as more likely when several of these come together [9][10]:
- Major surgery, especially of the abdomen, pelvis, hips or legs, and serious injury.
- Long periods without moving, including flights of more than 4 hours, bed rest or a leg in a cast.
- Estrogen from contraceptives or hormone therapy, pregnancy and the 3 months after giving birth.
- Obesity, diabetes, kidney disease, heart disease, high blood pressure, cancer and inflammatory bowel disease.
- A previous clot, an inherited clotting disorder or a family history; risk roughly doubles every 10 years after age 40.
Wegovy®-specific points before surgery or travel
Surgery is both a clot risk and a time when the Wegovy® label asks you to speak up: section 5.10 asks patients to tell their providers about Wegovy® before planned procedures with general anaesthesia or deep sedation, because of rare reports of stomach contents entering the lungs. [1] Mention any history of clots at the same conversation so the team can plan for both.
For travel, MedlinePlus suggests moving your legs often on long journeys and not smoking; people at very high risk may be prescribed a blood thinner for flights over 4 hours. [11] On Wegovy®, drinking enough fluids also matters on days with stomach side effects. [1] If you become pregnant, the label asks you to stop Wegovy® used for weight reduction, [1] and pregnancy itself raises clot risk. [10]
Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Sudden shortness of breath, chest pain that worsens on breathing in, coughing up blood, fainting or a racing heart | Emergency services (911 or local number) | Emergency | MedlinePlus [11] |
| A swollen, painful or tender leg, especially one leg | Your provider right away | Emergency | NHLBI [12] |
| Vomiting or diarrhea that will not settle, with little fluid kept down | Your prescriber | Today | Label §5.5 and §17 [1] |
| A planned operation or procedure with sedation, and a past clot or clotting disorder | Your surgical team and prescriber, in advance | At your next appointment | Label §5.10 [1]; CDC [10] |
| Estrogen-containing contraception or hormone therapy plus other clot risk factors | Raise at your next visit | At your next appointment | CDC [10] |
